Bolt Biotherapeutics, Inc.

NasdaqGS:BOLT Stock Report

Market Cap: US$21.8m

Bolt Biotherapeutics Valuation

Is BOLT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BOLT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BOLT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BOLT's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BOLT?

Key metric: As BOLT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BOLT. This is calculated by dividing BOLT's market cap by their current revenue.
What is BOLT's PS Ratio?
PS Ratio2.2x
SalesUS$9.78m
Market CapUS$21.81m

Price to Sales Ratio vs Peers

How does BOLT's PS Ratio compare to its peers?

The above table shows the PS ratio for BOLT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16.1x
GOVX GeoVax Labs
8.2x67.9%US$24.6m
PLUR Pluri
43.7xn/aUS$28.1m
PTN Palatin Technologies
7.7xn/aUS$17.9m
MRKR Marker Therapeutics
4.9x70.7%US$28.4m
BOLT Bolt Biotherapeutics
2.2x22.0%US$21.8m

Price-To-Sales vs Peers: BOLT is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (16.1x).


Price to Sales Ratio vs Industry

How does BOLT's PS Ratio compare vs other companies in the US Biotechs Industry?

131 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.6x21.4%
BOLT Bolt Biotherapeutics
2.2x22.0%US$21.81m
GILD Gilead Sciences
4x2.4%US$110.46b
BIIB Biogen
2.4x1.3%US$22.73b
BOLT 2.2xIndustry Avg. 9.6xNo. of Companies131PS01632486480+
131 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.6x28.4%
BOLT Bolt Biotherapeutics
2.2x2.6%US$21.81m
No more companies

Price-To-Sales vs Industry: BOLT is good value based on its Price-To-Sales Ratio (2.2x) compared to the US Biotechs industry average (10.1x).


Price to Sales Ratio vs Fair Ratio

What is BOLT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BOLT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.2x
Fair PS Ratio0.05x

Price-To-Sales vs Fair Ratio: BOLT is expensive based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BOLT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.57
US$1.75
+208.8%
14.3%US$2.00US$1.50n/a2
Nov ’25US$0.66
US$1.75
+165.8%
14.3%US$2.00US$1.50n/a2
Oct ’25US$0.65
US$1.75
+170.1%
14.3%US$2.00US$1.50n/a2
Sep ’25US$0.68
US$1.58
+133.7%
19.7%US$2.00US$1.25n/a3
Aug ’25US$0.73
US$1.25
+70.1%
16.3%US$1.50US$1.00n/a3
Jul ’25US$0.73
US$1.25
+70.8%
16.3%US$1.50US$1.00n/a3
Jun ’25US$0.76
US$1.94
+156.0%
62.1%US$4.00US$1.00n/a4
May ’25US$1.12
US$4.45
+297.3%
52.7%US$8.00US$1.25n/a5
Apr ’25US$1.50
US$4.45
+196.7%
52.7%US$8.00US$1.25n/a5
Mar ’25US$1.21
US$4.45
+267.8%
52.7%US$8.00US$1.25n/a5
Feb ’25US$1.11
US$4.45
+300.9%
52.7%US$8.00US$1.25n/a5
Jan ’25US$1.12
US$4.45
+297.3%
52.7%US$8.00US$1.25n/a5
Dec ’24US$0.89
US$4.80
+439.3%
40.4%US$8.00US$3.00n/a5
Nov ’24US$1.00
US$4.80
+380.0%
40.4%US$8.00US$3.00US$0.665
Oct ’24US$1.04
US$4.80
+361.5%
40.4%US$8.00US$3.00US$0.655
Sep ’24US$1.08
US$5.25
+386.1%
36.6%US$8.00US$3.00US$0.684
Aug ’24US$1.32
US$5.20
+293.9%
37.3%US$8.00US$3.00US$0.735
Jul ’24US$1.28
US$5.20
+306.3%
37.3%US$8.00US$3.00US$0.735
Jun ’24US$1.70
US$5.20
+205.9%
37.3%US$8.00US$3.00US$0.765
May ’24US$1.56
US$5.20
+233.3%
37.3%US$8.00US$3.00US$1.125
Apr ’24US$1.39
US$5.20
+274.1%
37.3%US$8.00US$3.00US$1.505
Mar ’24US$1.65
US$5.20
+215.2%
37.3%US$8.00US$3.00US$1.215
Feb ’24US$1.47
US$5.20
+253.7%
37.3%US$8.00US$3.00US$1.115
Jan ’24US$1.30
US$6.40
+392.3%
25.4%US$8.00US$4.00US$1.125
Dec ’23US$1.41
US$6.40
+353.9%
25.4%US$8.00US$4.00US$0.895
Nov ’23US$1.41
US$6.40
+353.9%
25.4%US$8.00US$4.00US$1.005

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies